Compounded peptides and compounded GLP-1 medications don't come from a single, uniform kind of pharmacy. U.S. law splits compounders into two distinct categories, 503A and 503B, named for the sections of the Federal Food, Drug, and Cosmetic Act that created them, and the difference has real consequences for oversight, quality control, and what a pharmacy is legally allowed to do.
503A: Traditional Compounding Pharmacies
A 503A pharmacy is the traditional model most people picture: a pharmacy that prepares a compounded medication for a specific, named patient, based on a prescription from that patient's own prescriber. 503A pharmacies operate under state board of pharmacy oversight and follow USP compounding standards (USP <795> for non-sterile preparations and USP <797> for sterile ones), but they are not required to meet the FDA's federal current Good Manufacturing Practice (cGMP) standards the way a drug manufacturer is, and they're generally limited to patient-specific prescriptions rather than producing medication in bulk ahead of demand.
503B: Outsourcing Facilities
A 503B pharmacy, more precisely called an "outsourcing facility," operates under a different section of the law created specifically to allow larger-scale compounding. 503B facilities can manufacture medications in batches, with or without patient-specific prescriptions, generally for sale to hospitals, clinics, or other healthcare facilities for office use. In exchange for that broader latitude, 503B facilities take on meaningfully more regulatory burden: they must register with the FDA, follow federal cGMP requirements under 21 CFR Parts 210 and 211, the same general framework that applies to conventional drug manufacturers, maintain independent quality-control functions, and report their compounded product lists to the FDA twice a year.
Why the Distinction Matters for Peptides
The bulk drug substances a pharmacy may legally use are governed separately from the 503A/503B distinction, through the FDA's Category 1 and Category 2 bulk substance lists discussed in this site's dedicated basics article, but the two systems interact: whether a peptide is eligible for compounding at all, and what kind of facility is preparing it, are both relevant questions for anyone trying to understand where a specific compounded product actually came from and what oversight applies to it. A 503A pharmacy filling an individual prescription and a 503B facility mass-producing a product are different businesses with different regulatory obligations, even when they're compounding the same underlying substance.
What This Means in Practice
Recent FDA enforcement action against telehealth companies and compounders selling GLP-1 and other peptide products, covered elsewhere on this site, has repeatedly centered on companies blurring these lines: marketing compounded products as equivalent to FDA-approved drugs, or obscuring which type of facility actually prepared a given product. A patient or consumer trying to evaluate a compounded peptide or GLP-1 product can reasonably ask which type of facility prepared it, whether it was tied to an individual prescription from their own provider, and whether that facility is registered and in good standing, questions that a legitimate pharmacy should be able to answer clearly.
The Bottom Line
503A and 503B are not interchangeable labels; they describe two different regulatory pathways with different oversight, different scale, and different legal requirements. Neither designation is a guarantee of safety or quality on its own, and compounded products, whatever the source, are not FDA-approved in the way a manufactured drug is. Anyone using a compounded peptide or medication should understand which pathway supplied it and raise questions about sourcing and oversight with their prescribing physician or pharmacist.